Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Pharmaceuticals  // Browsing posts in Pharmaceuticals

Teva’s Long-Term Success Will Depend on Strategic Acquisitions

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies: ACT, AZN, BIIB, HSP, MYL, NVS, PFE, SLXP, TSE:VRX, TLV:TEVA By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Ten sources who commented offered mixed responses on the likelihood of Teva Pharmaceutical Industries […]

Read more...

Teva Pharmaceuticals Whisper

Teva Pharmaceuticals Whisper

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies Covered: Teva Pharmaceuticals (TEVA), Novartis AG (NVS), Mylan (MYL) Report Available: March 25, 2015   Blueshift’s initial research shows Teva’s highly profitable MS drug, Copaxone, is nearing the patent cliff, though its patent-protected reformulation of […]

Read more...

Current Exparel Users Satisfied; FDA Concerns Create Potential Hurdles

Research Question: Has the FDA warning letter negatively affected use of Pacira Pharmaceutical’s Exparel? Companies: HCA, HYH, PCRX By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Two distinct schools of thought on the impact of a September FDA warning letter to Pacira Pharmaceuticals Inc. (PCRX) emerged in this report. Industry specialists […]

Read more...

Pacira Pharmaceuticals

Pacira Pharmaceuticals

Research Question: Has the FDA warning letter negatively impacted Pacira Pharmaceutical’s Exparel use? Companies Covered: Pacira Pharmaceuticals (PCRX) Report Available: Nov. 26, 2014   Blueshift’s initial research shows the FDA warning letter may be hampering Exparel use while the company awaits FDA approval for a nerve block indication.   Observations PCRX is a specialty pharmaceutical […]

Read more...

Market Conditions Prime for More Generic-Drug Price Increases

Research Question: Will declining competition and supply shortages in the generic drug segment continue to drive up prices, or will third-party payers, the FDA and Congress intervene? Companies: ABC, ACT, CAH, CVS, IPXL, LCI, MCK, MYL, RAD, TLV:TEVA, TSE:ENL, WAG, WMT By: David Franklin Click here to download the report (.pdf)   Summary of Findings The trend […]

Read more...

Generic Drug Pricing Whisper

Generic Drug Pricing Whisper

Research Question: Will declining competition and shortages in the generic drug segment continue to drive up prices, or will third-party payers, the FDA, and congress intervene? Companies Covered: Endo International plc (ENDP), Lannett Company, Inc. (LCI), Mylan Inc. (MYL), Actavis PLC (ACT) and Teva Pharmaceutical Industries Ltd. (TLV:TEVA/TEVA) Report Available: October 3, 2014   Blueshift’s initial research shows generic […]

Read more...

Aegerion Pharmaceuticals Whisper

Aegerion Pharmaceuticals Whisper

Research Question: Is the leveling off of Aegerion’s Juxtapid sales permanent or will sales growth return? Companies Covered: Aegerion Pharmaceuticals (AEGR), Isis Pharmaceuticals, Inc. (ISIS), Sanofi (SNY) Report Available: July 16, 2014   Blueshift’s initial research reveals Juxtapid sales slowing, possibly due to a smaller-than-expected patient population and cheaper alternatives, though the company received praise for […]

Read more...

Generic Drug Joint Purchasing Will Squeeze Manufacturers

Research Question: Will joint drug-purchasing agreements made by the largest pharmaceutical retailers and distributors achieve generic-drug price reductions? How will the generic drug channel be affected? Companies: ABC, ACT, BOM:500359, BOM:524715, CAH, COST, CVS, ESRX, KR, MCK, MYL, NVS, RAD, SWY, TLV:TEVA/TEVA, TSE:CTT, WAG, WMT By: David Franklin Click here to download the report (.pdf)   Summary of Findings […]

Read more...

Generic Drug Whisper

Generic Drug Whisper

Research Question: Will the recent joint drug-purchasing agreements by the largest pharmaceutical retailers and distributors achieve anticipated generic drug price reductions, and how will the generic drug channel be impacted? Companies Covered: Actavis (ACT) AmerisourceBergen (ABC), Cardinal Health (CAH), Celesio (CLSI.HM), CVS Caremark (CVS), Express Scripts (ESRX), Hospira (HSP), McKesson, (MCK), Mylan, (MYL), Novartis (NVS), Rite Aid (RAD), Teva […]

Read more...

Teva Turnaround Challenging But Likely with New CEO and Strong Initiatives

Research Question: Can Teva’s new CEO unify the company with a solution for its proprietary and generics businesses? Companies: ACT, ANIP, BIIB, BOM:524816, CAH, ETR:BAYN/BAYRY, MNTA, MYL, PATH, PFE, TLV:TEVA/TEVA By: David Franklin Click here to download the report (.pdf)   Summary of Findings Specific awareness of Teva Pharmaceutical Industries Ltd.’s (TLV:TEVA/TEVA) new CEO Erez Vigodman was limited, but […]

Read more...